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ascal J. Goldschmidt-Clermont, MD, FACC
urham, North Carolina
s early as in 1867, Cohnheim (1) noted that “all cells come
rom the bloodstream and therefore, in light of subsequent
bservations, from the bone marrow.” The identification of
ndothelial progenitor cells (EPCs), extracted from human
eripheral blood in 1997 by Asahara et al. (2), and subse-
uent studies have led to a significant paradigm shift in the
eld of vascular biology. The concept of arterial wall repair
ediated by bone marrow-derived EPCs was born, provid-
ng an alternative to the local “response to injury hypothesis”
or the development of atherosclerotic inflammation (Fig. 1)
3,4). According to this new theory, the arterial wall can
eal fairly well with multiple circulating and local noxious
timuli, as long as the bone marrow-derived repair capacity,
hich includes competent EPCs and probably progenitors
f other lineages, remains intact. Senescence of selected
See pages 1441 and 1449
one marrow pathways, a process that is accelerated by the
assage of time in the presence of risk factors, can lead to
he inability of the marrow to produce repair-competent
PCs and other marrow-derived progenitors (5,6). Hence,
reduced circulating EPC level has been proposed as a
ignificant risk factor for cardiovascular disease. When the
epair process becomes limiting, arterial cells, in particular
ndothelial cells (ECs), become senescent as manifested, for
xample, by the reduced length of chromosome telomeres
7,8). Thus, exogenous cells from young, but not old, bone
arrows have the ability to engraft and rejuvenate arterial
ntimal cells in mouse models of atherosclerosis, as evi-
enced by the elongation of telomeres of these cells (6). The
ack of ability for aging organisms to renew ECs exposed to
oxious stimuli leads to endothelial dysfunction and conse-
uent atherosclerosis genesis.
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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G 023073-01) and the Doris Duke Charitable Foundation (20030028) to Dr.
oldschmidt-Clermont.Dozens of publications have suggested a link among
educed circulating EPC levels, atherosclerosis, and its
hromboembolic complications, such as angina, myocardial
nfarction, and percutaneous coronary intervention. Re-
uced levels of EPC also have been linked to disorders that
roduce a heightened cardiovascular risk, such as diabetes
ellitus, renal failure, rheumatoid arthritis, and osteoarthri-
is, to name only a few (6–12). In this context, two
mportant papers in the current issue of the Journal inves-
igate the potential implications of circulating EPC levels in
atients with type II diabetes mellitus complicated with
eripheral vascular disease (PVD) (9) and the impact of
ging on circulating EPC changes in young and old healthy
ndividuals without major cardiovascular risk factors (10).
hese studies add a new dimension to our understanding of
he putative role of circulating EPCs in the pathogenesis of
ascular diseases, in particular in the context of diabetes and
ormal aging.
PCs, ENDOTHELIAL REGENERATION,
ND ATHEROSCLEROTIC INFLAMMATION
everal lines of evidence indicate that bone marrow-derived
PCs can be recruited to the ischemic limbs, brain, and
o myocardial infarcts of mice, accelerating the re-
ndothelialization process (reviewed by Rafii and Lyden
11]). Endothelialization in adult dog thoracic aorta Dacron
rafts was found to arise exclusively from transplanted bone
arrow (12). The CD34/VEGFR endothelial and he-
atopoietic precursors were recruited to the surface of left
entricular-assist devices in humans, rendering the surface
onthrombogenic (13). Furthermore, circulating EPCs
ould home to denuded parts of the artery after balloon
njury (14). Rauscher et al. (6) demonstrated that bone
arrow-derived EPCs engrafted the arterial wall of athero-
clerotic apoE-deficient mice. These data demonstrate the
lasticity of adult stem cells in differentiating into vascular
ells and their capacity in the prevention and treatment of
ardiovascular disease (15). However, aging in the presence
f risk factors can lead to the progressive depletion of
arrow cells that give rise to progenitors needed for arterial
epair.
Because the repair process originating from the marrow is
ecruited by cytokines, growth factors, and other proinflam-
atory elements (such as monocyte inflammatory peptide-
-alpha, monocyte chemotactic protein-1, interleukin
-beta, interleukin-6, tumor necrosis factor-alpha,
-reactive protein, and interferon-gamma), the delinquent
epair process can lead to progressive amplification of the
nflammatory signals due to the lack of a negative feedback
oop. These signals, in turn, contribute to the aggravated
nflammatory reaction (Th2-predominant) (4,16), further
amaging the arterial wall (positive feedback loop) (Fig. 1).
ence, the elevation of markers not only reflects the
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May 3, 2005:1458–60 Editorial Commentntensity of atherosclerotic inflammation but also may
dentify those individuals whose arterial repair is insufficient.
DENTIFICATION AND
HARACTERIZATION OF EPCs AND THEIR PRECURSORS
onsidering the growing evidence in support of circulating
PCs as a marker of vascular health, it would be helpful to
efine standards for measurements of this important vari-
ble. However, the molecular and phenotypic determinants
f EPCs and their precursors remain largely unknown.
ttempts to accurately characterize these cells have been
ampered by several hurdles (17). Indeed, a considerable
verlap exists among proteins expressed on the surface of
ngioblast-like EPCs, mature ECs sloughed from the vessel
all, and hematopoietic cells. Specifically, both putative
PCs with angioblastic potential and vessel wall-derived
ature ECs may express similar endothelial-specific mark-
rs, including vascular endothelial growth factor (VEGF)
eceptor-2 (VEGFR2, kinase insert domain receptor
KDR], flk-1), Tie-1, Tie-2, vascular endothelial-cadherin,
nd CD34 (18–20). Hematopoietic stem cells express
arkers that also are found on EPCs and mature ECs, such
s CD34, platelet endothelial cell adhesion molecule
CD31), Tie-1, Tie-2, von Willebrand factor, and VEGFR2
21). Consequently, an array of different methodologies has
een used to determine the number of circulating EPCs,
ncluding CD34, VEGFR2, CD133, CD34/
EGFR2, CD34/CD133/VEGFR2, CD34/CD117/
EGFR2 (mature EPCs), CD34/CD31, CD34/
1H12, CD133/VE-cadherin, CD34/CD14,
D34/CD14, 1,1=-dioctadecyl-3,3,3=,3=-tetramethyl-
igure 1. Effect of bone marrow obsolescence on arterial repair and
nflammation. In the presence of a competent bone marrow capable of
roducing the type of progenitor cells for arterial repair (young marrow),
nflammatory cytokines, growth factors, and other agonists contribute to
he recruitment of repair cells. Once the arterial lesion is repaired
uccessfully, the inflammatory markers subside (negative feedback loop). In
ontrast, if the bone marrow is unable to produce these progenitor cells,
ither because the pathways that are required for their production are
eficient or because the produced cells are somehow incompetent, the
nflammatory factors continue to increase, essentially indicating a persistent
rterial lesion. The increase in inflammatory factors, in turn, can further
romote arterial damage, with worsening of atherosclerosis and destabili-
ation of atherosclerotic plaques (positive feedback loop). CK  cytokines
nd other inflammation agonists; EPC  endothelial progenitor cell; GF
growth factors. Adapted from Goldschmidt-Clermont et al. (4).ndocarbocyanine-labeled acetylated low-density lipoprotein rptake/lectin binding, cKit/Sca-1, cKit, CD49d,
XCR4, and early- and late-outgrowth EPC colonies
22–29).
As a result, these variations in method have created
onfusion regarding data interpretation and may explain the
nconsistent results obtained in different studies. Indeed, the
onclusion by Heiss et al. (10) that normal aging resulted in
unctional deficits rather than depletion of EPCs is based on
he lack of numerical changes of CD34/KDR (VEGFR2)
r CD133/KDR double-positive cells and the decreased
umber of outgrowing ECs from the mononuclear fraction
f the peripheral blood. Although the finding that the
unctional capacity of circulating EPCs declines with aging
s intriguing, this conclusion may be challenged by the
ossibility that a subset of the cells that they surveyed, or
ven another group of bone marrow-derived progenitors
apable of differentiating to ECs, may have been depleted,
nbeknown to the investigators. The study by Fadini et al.
9), which quantified CD34 cells, defined as circulating
rogenitor cells, and CD34/KDR cells, defined as EPCs,
hows that PVD is associated with an extremely low number
f EPCs, underscoring the notion that the complicating
ascular injury in the presence of diabetes results in further
ecline in the EPC reservoir in the bone marrow and/or
urther impairment in EPC mobilization compared with
iabetes alone. However, it remains to be determined
hether changes in CD34/KDR cells do fully reflect
hanges in EPCs capable of arterial repair and angiogenic
ctivity.
ELEVANCE TO THE MANAGEMENT
F PATIENTS WITH ARTERIAL DISORDERS
rogress in managing atherosclerosis and related conditions,
uch as coronary artery disease, cerebral vascular disease, and
VD, has occurred through successive steps that include: 1)
natomical definition of the lesions (which has resulted in
ultiple techniques to image arterial lesions); 2) recognition
f risk factors for the pathogenesis and their control (which,
hus far, has the greatest impact on the disease process and
ts thromboembolic complications); 3) mechanistic insight
ith the characterization of the inflammation process (new
arkers for risk prediction have resulted from this advance);
nd 4) understanding of the arterial repair process that is
eeded to maintain arterial homeostasis and involves not
nly local reactions but importantly the recruitment of bone
arrow precursor cells. Inadequate repair is particularly
mportant because it may determine atherosclerosis initia-
ion, progression, and lesion destabilization. Hence, the
rogressive obsolescence of the bone marrow may account
or the powerful risk associated with aging (15).
The study by Heiss et al. (10) stresses the importance of
ging relative to the dysfunction of EPCs and, hence, cells
ecruited from the marrow in situations of acute coronary
yndromes, even in individuals without significant coronary
isk factors, may be incapable of arterial repair, leading to
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Editorial Comment May 3, 2005:1458–60xtensive destabilization of coronary vessels. Estrogens are
nown for their ability to stimulate the production of EPCs
30), but for aging women whose ability to produce these
ells may be already challenged, the addition of hormone
eplacement therapy might lead to acute disruption of
esidual repair capacity. The data of Fadini et al. (9) suggest
hat diabetes mellitus impacts negatively on the ability of
he bone marrow to mount the successful production of
PCs. Hence, the effect of diabetes on arterial disorders
uch as PVD may involve not only local effects on the
rterial wall but also a deleterious consequence for pathways
n the marrow that are responsible for producing an arma-
entarium of EPCs required for repair at various sites of
he arterial tree. Statins—drugs known for their remarkable
mpact on the prevention of arterial thrombotic events—
ay protect the marrow from the impact of aging, even
eyond what could be expected from the reduction of the
holesterol risk and consequent consumption of the arterial
epair potential of individual patients (29).
It is still unclear at the present time whether new
echniques will be successful in providing progenitor cells
apable of arterial repair to patients whose intrinsic capacity
as been eroded with aging and by risk factors. Such
echniques may involve: 1) the provision of allogeneic
rogenitors that would reconstitute the repair potential of
he affected patient; 2) the restitution of an intrinsic repair
unction through drug therapy and/or precursor cell pro-
essing; or 3) a combination of both approaches. Regardless
f the outcome of the eventual breakthrough technology,
his newest wave of EPC repair research is highly likely to
ave a substantial clinical impact on the cardiovascular
pidemic worldwide.
eprint requests and correspondence: Dr. Pascal J. Goldschmidt-
lermont, Division of Cardiology, Department of Medicine, Duke
niversity Medical Center, Box 3845, Durham, North Carolina
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